Next 10 |
2024-04-24 17:36:16 ET More on Dyadic International Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript Dyadic's Michael Tarnok to step down as Chairman of the board of directors Dyadic announces strategic partnership agreement to develop rabies v...
2024-03-28 22:22:08 ET Dyadic International, Inc. (DYAI) Q4 2023 Earnings Conference Call March 28, 2024 05:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Operating Of...
2024-03-28 16:03:21 ET More on Dyadic International Dyadic's Michael Tarnok to step down as Chairman of the board of directors Dyadic announces strategic partnership agreement to develop rabies vaccines Seeking Alpha’s Quant Rating on Dyadic International...
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibod...
2024-03-28 08:58:20 ET More on Dyadic International Dyadic announces strategic partnership agreement to develop rabies vaccines Seeking Alpha’s Quant Rating on Dyadic International Historical earnings data for Dyadic International Financial inform...
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins f...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction an...
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic&...
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction an...
News, Short Squeeze, Breakout and More Instantly...
Dyadic International Inc. Company Name:
DYAI Stock Symbol:
OTCMKTS Market:
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibod...
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a bi...
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins f...